Stockhub

Annovis Bio, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

18 August 2022

  • curprev 06:5706:57, 18 August 2022 >Paris 794 bytes +794 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also devel..."
Retrieved from "https://stockhub.co/research/Annovis_Bio,_Inc."